Livedoid Vasculopathy: Review of Pathogenesis, Clinical Presentation, Diagnostic Workup, and Treatment

G. Trey Haunson, DO, MS; David W. Judy, DO; Nicole C. Prall, MD; Richard A. Miller, DO

We report the case of a patient with livedoid vasculopathy that had been undiagnosed and inadequately treated for more than 10 years. To improve disease recognition and management, we review the pathogenesis, typical clinical presentation, diagnostic workup, and treatment options for livedoid vasculopathy.

Cutis. 2012;90:302-306.

Case Report

A 71-year-old man presented with a history of painful sores on both legs of more than 10 years' duration. The patient reported that he had previously consulted with multiple dermatologists and had "been told many things," but he claimed no one had helped him with his condition.

The patient's medical history was remarkable for hypertension, hypercholesterolemia, macrocytic anemia, gastroesophageal reflux disease, androgenetic alopecia, attention-deficit/hyperactivity disorder, depression, and a 4-vessel coronary artery bypass graft performed 10 years prior. His current medications included simvastatin (40 mg daily), valsartan (80 mg daily), clopidogrel bisulfate (75 mg daily), ketoprofen (200 mg daily), omeprazole (20 mg daily), finasteride (1 mg daily), folic acidcyanocobalamin-pyridoxine 2.5-25-2 mg daily), amphetamine-dextroamphetamine (40 mg daily), paroxetine hydrochloride (30 mg daily), venlafaxine hydrochloride extended release (225 mg daily), bupropion hydrochloride (300 mg daily), zinc (50 mg daily), selenium (200 mg daily), calcium

Correspondence: G. Trey Haunson, DO, MS, 520 Tower Rd, Christiansburg, VA 24073 (thaunson@yahoo.com).

(800 mg daily), and omega-3 (2 g daily). The patient reported no known drug allergies. His family history was remarkable for myocardial infarction in his father and 6 of 11 siblings as well as cerebrovascular accident in his mother; no relatives reported experiencing symptoms similar to the patient's current presentation. He denied a history of smoking or use of alcohol or illegal drugs. A review of systems was positive for easy bruising but otherwise was negative. The patient denied any history of lower extremity deep vein thrombosis or thrombophlebitis.

On physical examination the lower extremities revealed 3+ pitting edema, palpable posterior tibial and dorsalis pedis artery pulses, and a capillary refill time of less than 3 seconds. Hair growth was noted on the bilateral lower legs but was absent on the bilateral feet and toes. Plantar sensation to monofilament was intact (10/10) bilaterally. Tender punched out ulcers and stellate atrophic hypopigmented plaques (Figure 1) with peripheral hyperpigmentation, erythema, and telangiectasia (Figure 2) were seen bilaterally. In total, 6 ulcers of variable size were found on the shins and surrounding the malleoli.

Venous ultrasound of the bilateral lower extremities showed no evidence of deep vein thrombosis. The ankle brachial index was normal (left, 1.04; right, 1.05). Wound cultures were negative. A 4-mm punch biopsy was taken from the left calf. The histologic findings demonstrated a mild perivascular infiltrate with red blood cell extravasation. The walls of the dermal vessels showed thickening and hyalinization of the tunica intima (Figure 3). These findings were consistent with a diagnosis of livedoid vasculopathy.

The patient was referred to our wound care center and was treated with compression therapy. The ulcerations were covered with a silver-impregnated dressing and 2-layer knee-high elastic compression wraps. The patient attended weekly follow-up appointments for dressing changes; by the third follow-up the

WWW.CUTIS.COM

Copyright Cutis 2012. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

Drs. Haunson, Judy, and Miller are from Largo Medical Center, Florida. Dr. Prall is from Global Pathology, Miami Lakes, Florida. The authors report no conflict of interest.



Figure 1. Punched out ulcers and stellate atrophie blanche.

ulcers had completely epithelialized. The patient subsequently refused workup for underlying systemic coagulopathy.

Comment

Livedoid vasculopathy is a disorder of the blood vessels most commonly seen in adult women. The pathogenesis is not well understood but is believed to involve alteration of local or systemic control of coagulation, causing formation of fibrin thrombi focally within the superficial dermal blood vessels. Thrombosis causes superficial tissue ischemia and necrosis with resulting pain and ulceration.¹



Figure 2. Reticulated atrophie blanche with peripheral hyperpigmentation, erythema, and telangiectasia.




Figure 3. Mild perivascular infiltrate with red blood cell extravasation and thickening of vessel walls with hyalinization of the tunica intima (H&E, original magnification \times 60).

Patients with livedoid vasculopathy clinically present with chronic painful ulceration and scarring of the lower extremities. The ulcers favor the distal lower extremities, particularly around the malleoli. Ulcers are punched out and slowly heal to form stellate, reticulated, atrophic scars known as atrophie blanche. Peripheral telangiectasia, erythema, hyperpigmentation, and/or purpura may be present. It also is common for livedoid vasculopathy to

WWW.CUTIS.COM

VOLUME 90, DECEMBER 2012 303

Copyright Cutis 2012. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

present as chronic atrophie blanche with no history of ulceration. $^{\rm 2}$

The differential diagnosis of ulceration on the legs is broad, and atrophie blanche is not specific to livedoid vasculopathy. Ulceration also can result from vasculitides such as small-vessel vasculitis, microscopic polyarteritis, polyarteritis nodosa, and granulomatous vasculitis, as well as peripheral vascular disease resulting from venous or arterial insufficiency.^{3,4} Leg ulceration is a possible complication from treatment with hydroxyurea.³ Various systemic coagulopathies have been observed in patients with livedoid vasculopathy, suggesting that dermal thrombosis plays a primary role in the disease pathogenesis.⁵ These coagulopathies include the antiphospholipid syndrome,⁶⁻⁹ dysproteinemias,3 genetic thrombophilic disorders such as factor V Leiden (R506Q) mutation,¹ deficiency in protein C or S,^{10,11} hyperhomocysteinemia,¹² sickle cell anemia, and other disorders of abnormal platelet activation or fibrinolysis.¹³⁻¹⁶

A thorough clinical history that rules out other common causes of atrophie blanche as well as a tissue biopsy may help to definitively diagnose livedoid vasculopathy. Because biopsy sites typically have a prolonged healing time, repeat biopsies are discouraged.^{3,5} Characteristic findings include intraluminal thrombosis, fibrin deposition, endothelial proliferation, hyalinized degeneration of the subintimal layer of superficial dermal vessels with extravasated red blood cells, and mild perivascular lymphocytic infiltrates.¹⁷ The term vasculopathy is preferred over vasculitis, as the inflammatory component is minimal.¹ Immunofluorescence findings are nonspecific and include superficial vessel deposition of immunoglobulins, complement components, and fibrin, suggesting a possible immune-mediated component to the pathogenesis.3,18

The diagnostic workup should first rule out common causes of atrophie blanche such as venous insufficiency. Although our patient's symptoms were not directly caused by venous disease, we feel it did aggravate the underlying livedoid vasculopathy. Venous insufficiency is easily treated with compression therapy. Although venous stasis is the most common cause of atrophie blanche, livedoid vasculopathy is not diagnosed without a component of dermal intravascular thrombosis. The physician also can search for an underlying systemic coagulation defect; however, we do not feel it is necessary to order the entire coagulopathy profile unless systemic symptoms suggest otherwise.

Various treatment modalities for livedoid vasculopathy have been documented.¹⁹ Basic wound care including zinc oxide, glycerin, gelatin bandages should be employed. Physical modalities such as leg elevation and compression stockings also are extremely effective.^{1,20} Any underlying coagulation disorder should be specifically addressed. Elevated levels of homocysteine or a mutation of methylenetetrahydrofolate reductase respond to treatment with folic acid and possibly vitamin B complex^{21,22}; idiopathic cryofibrinogenemia responds to treatment with anabolic steroids such as danazol, stanozolol, or ethylestrenol.²³⁻²⁶ Tissue plasminogen activator and other antithrombotics have been shown to be efficacious in some patients^{14,27,28}; however, the potential benefits must be weighed against the risk for complications as well as the high cost of treatment and necessity for inpatient administration. Antiplatelet agents such as aspirin, dipyridamole, ticlopidine, pentoxifylline, ketanserin, and prostacyclin analogues iloprost and beraprost have been successfully used.7,15,29-37 Vitamin K antagonists such as warfarin and heparin are effective in some patients when used as monotherapies.^{4,38-46} Low-molecular-weight heparin (enoxaparin sodium) is recommended for use only in patients who are refractory to antiplatelet and vitamin K antagonists due to cost, compliance with injections, and the longterm risk for osteoporosis.44,46 Corticosteroids have a fibrinolytic effect, but additional benefit from an anti-inflammatory component cannot be excluded.²⁷ Psoralen plus UVA light therapy has helped some patients.47,48 Antimalarial drugs such as hydroxychloroquine have been utilized in patients with lupus or antiphospholipid antibodies and atrophie blanche. Patients with atrophie blanche-like lesions who currently are taking hydroxyurea may need a trial period off the drug, as hydroxyurea may mimic this syndrome through unknown mechanisms.³ Other treatment options include hyperbaric oxygen,^{49,50} intravenous immunoglobulins,^{51,52} niacin,² dihydropyridine calcium channel blockers such as nifedipine,46 and immunosuppressive therapies.53 Combination therapies also have been reported to be effective.^{3,46} Smoking cessation also should be encouraged.³

Conclusion

Livedoid vasculopathy is a clinical syndrome of chronic painful ulceration of the lower extremities and atrophie blanche in the context of histologic evidence of intraluminal thrombosis of dermal vessels and is commonly seen in conjunction with systemic coagulation abnormalities. Underdiagnosis and inappropriate management of the disorder have been the result of numerous challenges in diagnosis, including a nebulous etymology, broad differential diagnosis of leg ulceration and atrophie blanche, concomitant systemic coagulopathies, and lack of standard treatment guidelines. Treatment options are varied and include managing specific underlying coagulation

Copyright Cutis 2012. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

disorders, platelet activation, and fibrinolysis. Proper wound care in patients with livedoid vasculopathy is essential. With the addition of the correct dressing to maintain an effective environment for healing in combination with compression therapy, our patient had dramatic improvement. In our experience, systemic medications such as aspirin, pentoxifylline, and danazol are helpful and may be added if symptoms do not improve or worsen.

REFERENCES

- Calamia KT, Balabanova M, Perniciaro C, et al. Livedo (livedoid) vasculitis and the factor V Leiden mutation: additional evidence for abnormal coagulation. J Am Acad Dermatol. 2002;46:133-137.
- 2. Winkelmann RK, Schroeter AL, Kierland RR, et al. Clinical studies of livedoid vasculitis: (segmental hyalinizing vasculitis). *Mayo Clin Proc.* 1974;49:746-750.
- 3. Callen JP. Livedoid vasculopathy: what it is and how the patient should be evaluated and treated. *Arch Dermatol*. 2006;142:1481-1482.
- Davis MD, Wysokinski WE. Ulcerations caused by livedoid vasculopathy associated with a prothrombotic state: response to warfarin. J Am Acad Dermatol. 2008;58: 512-515.
- 5. Hairston BR, Davis MD, Pittelkow MR, et al. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. *Arch Dermatol.* 2006;142:1413-1418.
- 6. Lie JT. Vasculopathy in the antiphospholipid syndrome: thrombosis or vasculitis, or both? *J Rheumatol*. 1989;16: 713-715.
- Grob JJ, Bonerandi JJ. Cutaneous manifestations associated with the presence of the lupus anticoagulant. a report of two cases and a review of the literature. J Am Acad Dermatol. 1986;15(2, pt 1):211-219.
- Alegre VA, Winkelmann RK, Gastineau DA. Cutaneous thrombosis, cerebrovascular thrombosis, and lupus anticoagulant—the Sneddon syndrome: report of 10 cases. *Int J Dermatol.* 1990;29:45-49.
- Acland KM, Darvay A, Wakelin SH, et al. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? *Br J Dermatol*. 1999;140:131-135.
- Baccard M, Vignon-Pennamen MD, Janier M, et al. Livedo vasculitis with protein C system deficiency. *Arch Dermatol*. 1992;128:1410-1411.
- Boyvat A, Kundakçi N, Babikir MO, et al. Livedoid vasculopathy associated with heterozygous protein C deficiency. Br J Dermatol. 2000;143:840-842.
- Gibson GE, Li H, Pittelkow MR. Homocysteinemia and livedoid vasculitis. J Am Acad Dermatol. 1999;40 (2, pt 1):279-281.
- Pizzo SV, Murray JC, Gonias SL. Atrophie blanche: a disorder associated with defective release of tissue plasminogen activator. Arch Pathol Lab Med. 1986;110: 517-519.

- Klein KL, Pittelkow MR. Tissue plasminogen activator for treatment of livedoid vasculitis. Mayo Clin Proc. 1992;67:923-933.
- Tsutsui K, Shirasaki F, Takata M, et al. Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation. *Dermatology*. 1996;192:120-124.
- Papi M, Didona B, DePità O, et al. Livedo vasculopathy vs small vessel cutaneous vasculitis: cytokine and platelet P-selectin studies. Arch Dermatol. 1998;134:447-452.
- 17. Bard JW, Winkelmann RK. Livedo vasculitis. segmental hyalinizing vasculitis of the dermis. *Arch Dermatol*. 1967;96:489-499.
- Schroeter AL, Diaz-Perez JL, Winkelmann RK, et al. Livedo vasculitis (the vasculitis of atrophie blanche). immunohistopathologic study. Arch Dermatol. 1975;111:188-193.
- Milstone LM, Braverman IM, Lucky P, et al. Classification and therapy of atrophie blanche. Arch Dermatol. 1983;119:963-969.
- Yang LJ, Chan HL, Chen SY, et al. Atrophie blanche. a clinicopathological study of 27 patients. *Changgeng Yi Xue* Za Zhi. 1991;14:237-245.
- 21. Rampf J, Sunderkötter C, Hirschfeld G, et al. Methylenetetrahydrofolate reductase polymorphism associated with moderate hyperhomocysteinemia in a patient with livedo vasculopathy: treatment with vitamin supplementation and low molecular weight heparin. *Br J Dermatol.* 2006;155:850-852.
- 22. Meiss F, Marsch WC, Fischer M. Livedoid vasculopathy. the role of hyperhomocysteinemia and its simple therapeutic consequences. *Eur J Dermatol.* 2006;16:159-162.
- 23. Gilliam JN, Herndon JH, Prystowsky SD. Fibrinolytic therapy for vasculitis of atrophie blanche. *Arch Dermatol*. 1974;109:664-667.
- 24. Hsiao GH, Chiu HC. Low-dose danazol in the treatment of livedoid vasculitis. *Dermatology*. 1997;194:251-255.
- 25. Wakelin SH, Ellis JP, Black MM. Livedoid vasculitis with anticardiolipin antibodies: improvement with danazol. *Br J Dermatol.* 1998;139:935-937.
- Falanga V, Kirsner R, Eaglstein WH, et al. Stanozolol in treatment of leg ulcers due to cryofibrinogenaemia. *Lancet*. 1991;338:347-348.
- 27. Murrell DF, Jensen J, O'Keefe EJ. Failure of livedoid vasculitis to respond to tissue plasminogen activator. Arch Dermatol. 1995;131:231-232.
- 28. Deng A, Gocke CD, Hess J, et al. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator. *Arch Dermatol.* 2006;142:1466-1469.
- 29. Drucker CR, Duncan WC. Antiplatelet therapy in atrophie blanche and livedo vasculitis. *J Am Acad Dermatol*. 1982;7:359-363.
- Kern AB. Atrophie blanche. report of two patients treated with aspirin and dipyridamole. J Am Acad Dermatol. 1982;6:1048-1053.

VOLUME 90, DECEMBER 2012 305

Copyright Cutis 2012. No part of this publication may be reproduced, stored, or transmitted without the prior written permission of the Publisher.

- 31. Grob JJ, Bonerandi JJ. Thrombotic skin disease as a marker of the anticardiolipin syndrome. livedo vasculitis and distal gangrene associated with abnormal serum antiphospholipid activity. J Am Acad Dermatol. 1989;20:1063-1069.
- Yamamoto M, Danno K, Shio H, et al. Antithrombotic treatment in livedo vasculitis. J Am Acad Dermatol. 1988;18(1, pt 1):57-62.
- 33. Sauer GC. Pentoxifylline (Trental) therapy for the vasculitis of atrophie blanche. *Arch Dermatol.* 1986;122:380-381.
- 34. Sams WM Jr. Livedo vasculitis. therapy with pentoxifylline [erratum in Arch Dermatol. 1989;125:368]. Arch Dermatol. 1988;124:684-687.
- 35. Ely H, Bard JW. Therapy of livedo vasculitis with pentoxifylline. *Cutis.* 1988;42:448-453.
- Rustin MH, Bunker CB, Dowd PM. Chronic leg ulceration with livedoid vasculitis, and response to oral ketanserin. Br J Dermatol. 1989;120:101-105.
- 37. Magy N, Algros MP, Racadot E, et al. Livedoid vasculopathy with combined thrombophilia: efficacy of iloprost [in French]. *Rev Med Interne*. 2002;23:554-557.
- Dedichen J, Gjessing HC. Livedo reticularis with summer ulcerations; report of a case treated with long-term anticoagulation therapy. Acta Med Scand Suppl. 1956;319:74-78.
- Champion RH. Livedo reticularis with recurrent ulceration treated with anticoagulants. Br J Dermatol. 1962;74:195-196.
- 40. Borrie PF. Livedo reticularis. Proc R Soc Med. 1958;51: 324-325.
- Jetton RL, Lazarus GS. Minidose heparin therapy for vasculitis of atrophie blanche. J Am Acad Dermatol. 1983;8:23-26.
- 42. Browning CE, Callen JP. Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia. *Arch Dermatol.* 2006;142:75-78.

- 43. Heine KG, Davis GW. Idiopathic atrophie blanche: treatment with low-dose heparin. Arch Dermatol. 1986; 122:855-856.
- 44. Francès C, Barete S. Difficult management of livedoid vasculopathy. Arch Dermatol. 2004;140:1011.
- 45. Jetton RL, Lazarus GS. Minidose heparin therapy for vasculitis of atrophie blanche. J Am Acad Dermatol. 1983; 8:23-26.
- Hairston BR, Davis MD, Gibson LE, et al. Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases. Arch Dermatol. 2003;139:987-990.
- 47. Lee JH, Choi HJ, Kim SM, et al. Livedoid vasculitis responding to PUVA therapy. *Int J Dermatol.* 2001; 40:153-157.
- Choi HJ, Hann SK. Livedo reticularis and livedoid vasculitis responding to PUVA therapy. J Am Acad Dermatol. 1999;40(2, pt 1):204-207.
- 49. Juan WH, Chan YS, Lee JC, et al. Livedoid vasculopathy: long-term follow-up results following hyperbaric oxygen therapy. *Br J Dermatol.* 2006;154:251-255.
- Yang CH, Ho HC, Chan YS, et al. Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen. Br J Dermatol. 2003;149:647-652.
- Schanz S, Ulmer A, Fierlbeck G. Intravenous immunoglobulin in livedo vasculitis: a new therapeutic option? J Am Acad Dermatol. 2003;49:555-556.
- 52. Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: an open trial evaluating 9 consecutive patients. *J Am Acad Dermatol.* 2004;51:574-579.
- 53. Lee SS, Ang P, Tan SH. Clinical profile and treatment outcome of livedoid vasculitis: a case series. *Ann Acad Med Singapore*. 2003;32:835-839.